Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | DRD2 | P14416 | 1/20 | 0.33 |
| ▸ | DRD4 | P21917 | 1/20 | 0.33 |
| ▸ | DRD3 | P35462 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.32 |
| ▸ | TSHR | P16473 | 2/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6205520 | 1.00 | LMNA (0.33) | LMNADRD2DRD4DRD3ALDH1A1 | |
| SCHEMBL6201692 | 0.93 | DRD2 (0.40) | LMNADRD2DRD4DRD3ALDH1A1 | |
| SCHEMBL6202160 | 0.93 | DRD2 (0.40) | LMNADRD2DRD4DRD3ALDH1A1 | |
| SCHEMBL6204862 | 0.84 | LMNA (0.36) | LMNADRD2ALDH1A1CYP3A4CYP2D6 | |
| SCHEMBL6203490 | 0.84 | LMNA (0.36) | LMNADRD2ALDH1A1CYP3A4CYP2D6 | |
| SCHEMBL5729832 | 0.78 | DRD2 (0.54) | LMNADRD2DRD4DRD3ALDH1A1 | |
| SCHEMBL5764664 | 0.77 | LMNA (0.38) | LMNAALDH1A1CYP3A4CYP2D6TSHR | |
| SCHEMBL5765990 | 0.77 | LMNA (0.38) | LMNAALDH1A1CYP3A4CYP2D6TSHR | |
| SCHEMBL5766908 | 0.77 | LMNA (0.38) | LMNAALDH1A1CYP3A4CYP2D6TSHR | |
| SCHEMBL4906723 | 0.77 | LMNA (0.38) | LMNAALDH1A1CYP3A4CYP2D6TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1401839-B9 | ANTIDEPRESSANT (SSSRI) AZAHETEROCYCLYMETHYL DERIVATIVES OF 7,8-DIHYDRO-3H-T,9-DIOXA-1,3-DIAZACYCLOPENTA [A] NAPHTHALENE | WYETH CORP (US) | 2005-11-30 | — | — | EP | disclosed |
| EP-1401839-B1 | ANTIDEPRESSANT (SSSRI) AZAHETEROCYCLYMETHYL DERIVATIVES OF 7,8-DIHYDRO-3H-T,9-DIOXA-1,3-DIAZACYCLOPENTA [A] NAPHTHALENE | WYETH CORP (US) | 2005-09-07 | — | — | EP | disclosed |
| US-6927226-B2 | Antidepressant azaheterocyclymethyl derivatives of 7,8-dihydro-3H-6,9-dioxa-1,3-diazacyclopenta[a]naphthalene | WYETH (US) | 2005-08-09 | — | — | US | disclosed |
| EP-1401839-A1 | ANTIDEPRESSANT (SSSRI) AZAHETEROCYCLYMETHYL DERIVATIVES OF 7,8-DIHYDRO-3H-T,9-DIOXA-1,3-DIAZACYCLOPENTA A]NAPHTHALENE | Wyeth (US) | 2004-03-31 | — | — | EP | disclosed |
| US-20040010006-A1 | Antidepressant azaheterocyclylmethyl derivatives of 7,8-dihydro-3H-6,9-dioxa-1,3-diazacyclopenta[a]naphthalene | WYETH | 2004-01-15 | — | — | US | disclosed |
| US-6573283-B2 | For therapy of depression, obsessive compulsive disorder, panic attacks, generalized anxiety disorder, social anxiety disorder, sexual dysfunction, eating disorders, obesity, addictive disorders caused by ethanol or cocaine abuse | WYETH | 2003-06-03 | — | — | US | disclosed |
| US-20020183351-A1 | Antidepressant azaheterocyclylmethyl derivatives of 7,8-dihydro-3H-6,9-dioxa-1,3-diazacyclopenta[a]naphthalene | WYETH (US) | 2002-12-05 | — | — | US | disclosed |
| WO-2002088131-A1 | ANTIDEPRESSANT (SSSRI) AZAHETEROCYCLYMETHYL DERIVATIVES OF 7,8-DIHYDRO-3H-T,9-DIOXA-1,3-DIAZACYCLOPENTA[A]NAPHTHALENE | WYETH (US) | 2002-11-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040010006-A1 | Antidepressant azaheterocyclylmethyl derivatives of 7,8-dihydro-3H-6,9-dioxa-1,3-diazacyclopenta[a]naphthalene | OPRD1, OPRK1, HSD17B11 | LMNA 2909/4885DRD2 4/4885DRD4 18/4885 |
| US-20020183351-A1 | Antidepressant azaheterocyclylmethyl derivatives of 7,8-dihydro-3H-6,9-dioxa-1,3-diazacyclopenta[a]naphthalene | OPRD1, OPRK1, HSD17B11 | LMNA 2909/4885DRD2 4/4885DRD4 18/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.